Acadia snags Amgen, Horizon vet to direct R&D; Samantha Truex steps down as Upstream Bio CEO

→ Just a few weeks af­ter Am­gen tout­ed its ef­forts in rare dis­ease, EVP of R&D in that ther­a­peu­tic area is de­part­ing to lead R&D at Aca­dia Phar­ma­ceu­ti­cals. Eliz­a­beth Thomp­son will steer re­search and de­vel­op­ment at the neu­ro­science drug­mak­er af­ter serv­ing in key roles on the pre- and post-mar­ket­ing work of Hori­zon’s med­i­cines. She con­tributed to Te­pez­za, Krys­texxa and Up­liz­na, among oth­er drugs, dur­ing her time at the Chica­go and Ire­land bio­phar­ma, which Am­gen bought last year for near­ly $28 bil­lion. She joins Aca­dia about 13 months af­ter it se­cured its sec­ond FDA ap­proval. Her ca­reer in­cludes a pri­or 10-year tenure at Am­gen and roles at In­ter­Mune, Rap­tor and Ab­b­Vie.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.